Drug Asset Due DiligenceRequest a review
Built for

Teams making transaction-grade decisions.

Used by teams evaluating a drug asset ahead of licensing, acquisition, investment, or partnership.

Pharma BD teams
Biotech executives
Venture investors
PE healthcare investors
Corporate development
Licensing teams
Asset acquisition teams
Old vs. new

Two ways to evaluate the same asset.

Old way
  • Manual document review
  • Separate expert workstreams
  • Slow synthesis
  • Risk buried in notes
  • Limited cross-domain reasoning
Alenvo-connected workflow
  • Structured asset review
  • Cross-domain risk reasoning
  • Faster signal extraction
  • Clear executive outputs
  • Better diligence questions

Continue exploring

What we evaluate

Twelve domains assessed in every review.

Diligence outputs

What you receive after a review.

Request a review

Start a scoped conversation.

Before the term sheet

Understand the asset risk before you commit capital.

A short conversation is enough to scope a meaningful diligence review, tailored to your asset stage and decision window.

Request a diligence review See what we evaluate

No confidential information required to start the conversation.